Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

• Status: Completed
• Trial end date: 2021-01-22
• Target enrollment: 0
• Participant gender: All

Summary

Perform a randomized comparison study of dual-antiplatelet (aspirin, prasugrel) and triple-antiplatelet (aspirin, clopidogrel, and cilostazol) preparation using P2Y12 assay in patients with high on-treatment platelet reactivity undergoing stent-assisted coil embolization for an unruptured intracranial aneurysm

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Seoul National University Bundang Hospital
• Treatments: Aspirin; Cilostazol; Clopidogrel; Prasugrel Hydrochloride; Ticlopidine

Criteria

Inclusion Criteria:

• patients with clopidogrel resistance (greater than 220 P2Y12 reaction units using VerifyNow)

• patients with unruptured intracranial aneurysms

• patients over 20 years old

• patients who can communicate with each other

• patients who agreed to this study (with informed consent)

Exclusion Criteria:

• patients with recurrent aneurysms after coiling or clipping

• patients with allergic reaction to antiplatelets

• patients with high risks of hemorrhage

• patients with coagulopathy

• patients with thrombocytopenia (<100,000/mm3)

• patients with liver disease (> 100 of aspartate aminotransferase or alanine aminotransferase)

• patients with renal disease (> 2mg/dL of serum creatinine)

• patients with uncontrolled heart failure or angina

• patients with malignant tumor

• pregnant patients

• patients with past history that may associated with headache, including subarachnoid hemorrhage, head trauma, intracerebral hemorrhage, trigeminal neuralgia, arteriovenous malformation, brain tumor)

• Patients who are determined to be disqualified by researchers